CN1437480A - 治疗粘膜感染的组合物和方法 - Google Patents

治疗粘膜感染的组合物和方法 Download PDF

Info

Publication number
CN1437480A
CN1437480A CN01811367A CN01811367A CN1437480A CN 1437480 A CN1437480 A CN 1437480A CN 01811367 A CN01811367 A CN 01811367A CN 01811367 A CN01811367 A CN 01811367A CN 1437480 A CN1437480 A CN 1437480A
Authority
CN
China
Prior art keywords
composition
adjuvant
nthi
bacteria
microorganism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01811367A
Other languages
English (en)
Chinese (zh)
Inventor
R·L·克阑希
G·庞
M·L·邓克利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pneumobiotics Pty Ltd
Original Assignee
Pneumobiotics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pneumobiotics Pty Ltd filed Critical Pneumobiotics Pty Ltd
Publication of CN1437480A publication Critical patent/CN1437480A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN01811367A 2000-05-19 2001-05-21 治疗粘膜感染的组合物和方法 Pending CN1437480A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ7612A AUPQ761200A0 (en) 2000-05-19 2000-05-19 Compositions and methods for treatment of mucosal infections
AUPQ7612 2000-05-19

Publications (1)

Publication Number Publication Date
CN1437480A true CN1437480A (zh) 2003-08-20

Family

ID=3821690

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01811367A Pending CN1437480A (zh) 2000-05-19 2001-05-21 治疗粘膜感染的组合物和方法

Country Status (10)

Country Link
US (1) US8637051B2 (enExample)
EP (1) EP1305042B1 (enExample)
JP (2) JP5567756B2 (enExample)
KR (1) KR20030019389A (enExample)
CN (1) CN1437480A (enExample)
AT (1) ATE535284T1 (enExample)
AU (1) AUPQ761200A0 (enExample)
BR (1) BR0110971A (enExample)
CA (1) CA2409813C (enExample)
WO (1) WO2001087332A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103037887A (zh) * 2010-06-25 2013-04-10 国家医疗保健研究所 用于治疗呼吸道感染的方法和药物组合物
CN111529703A (zh) * 2020-06-17 2020-08-14 湖南唯乐可健康产业有限公司 一种组合物及其制备方法与在制备免疫佐剂中的应用
CN113855791A (zh) * 2014-05-02 2021-12-31 Qu生物制药公司 抗微生物免疫调节

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
WO2005077409A1 (en) * 2004-02-18 2005-08-25 The University Of Newcastle Research Associates Limited A vaccine formulated for administration to mucosa of the lungs
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
EP1793848A4 (en) * 2004-08-17 2008-06-11 Hunter Immunology Ltd METHOD OF DETERMINING A DOSAGE FOR ORAL INACTIVE VACCINE
ATE526978T1 (de) 2004-08-17 2011-10-15 Hunter Immunology Ltd Verfahren zur herstellung von oral abgetöteten vakzinen
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US8857659B2 (en) 2010-03-18 2014-10-14 Eveready Battery Company, Inc. Button cell battery dispenser package
US20140275420A1 (en) 2011-08-22 2014-09-18 Carnegie Mellon University Atom transfer radical polymerization under biologically compatible conditions
US9982070B2 (en) 2015-01-12 2018-05-29 Carnegie Mellon University Aqueous ATRP in the presence of an activator regenerator
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
AU2021252164A1 (en) 2020-04-09 2022-12-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
WO2024234034A1 (en) * 2023-05-12 2024-11-21 Biomune Pty Ltd Compositions and methods for preventative treatments for mucosal associated ailments

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA907737B (en) * 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
US6231870B1 (en) * 1995-06-02 2001-05-15 Uab Research Foundation Oral administration of pneumoccal antigens
JPH0680575A (ja) * 1991-03-05 1994-03-22 Meiji Milk Prod Co Ltd 経口免疫賦活剤
ES2262181T3 (es) 1996-05-31 2006-11-16 National University Of Ireland, Maynooth Il-12 como adyuvante en la vacuna contra la especie bordetella pertussis.
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
WO1999012416A1 (en) * 1997-09-09 1999-03-18 The Trustees Of Columbia University In The City Of New York T-independent conjugate-vaccines
US6153182A (en) 1997-12-19 2000-11-28 Uab Research Foundation Lymphotactin as an adjuvant
PL341697A1 (en) 1997-12-23 2001-04-23 Genesis Res & Dev Corp Ltd Compositions derived from mycobacterium vaccae and methods of using them
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
GB9801870D0 (en) * 1998-01-28 1998-03-25 Raby Limited Vaccine composition
DE69942214D1 (de) 1998-02-05 2010-05-12 Glaxosmithkline Biolog Sa Verfahren zur Reinigung oder Herstellung der MAGE Protein
SE9800615D0 (sv) * 1998-02-27 1998-02-27 Ingvar Sjoeholm Mucosal microparticle conjugate vaccine
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
CN1298307A (zh) 1998-03-05 2001-06-06 俄亥俄医学院 通过鼻内接种il－12加强免疫性
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
EP1087788A1 (fr) * 1998-06-26 2001-04-04 Aventis Pasteur Immunisation a ciblage mucosal
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US20020044926A1 (en) * 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
EP1303300B1 (en) * 2000-06-19 2010-08-11 Hunter Immunology Limited Compositions and methods for treatment of candidiasis
NZ523995A (en) * 2000-08-08 2005-03-24 Genesis Res & Dev Corp Ltd Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103037887A (zh) * 2010-06-25 2013-04-10 国家医疗保健研究所 用于治疗呼吸道感染的方法和药物组合物
CN103037887B (zh) * 2010-06-25 2017-11-10 国家医疗保健研究所 用于治疗呼吸道感染的方法和药物组合物
CN113855791A (zh) * 2014-05-02 2021-12-31 Qu生物制药公司 抗微生物免疫调节
CN111529703A (zh) * 2020-06-17 2020-08-14 湖南唯乐可健康产业有限公司 一种组合物及其制备方法与在制备免疫佐剂中的应用
CN111529703B (zh) * 2020-06-17 2023-09-15 湖南循天然营养有限公司 一种组合物及其制备方法与在制备免疫佐剂中的应用

Also Published As

Publication number Publication date
CA2409813A1 (en) 2001-11-22
BR0110971A (pt) 2005-04-05
JP2003533489A (ja) 2003-11-11
EP1305042A4 (en) 2005-02-02
WO2001087332A1 (en) 2001-11-22
EP1305042A1 (en) 2003-05-02
JP2012153706A (ja) 2012-08-16
EP1305042B1 (en) 2011-11-30
ATE535284T1 (de) 2011-12-15
US20040057965A1 (en) 2004-03-25
AUPQ761200A0 (en) 2000-06-15
CA2409813C (en) 2013-11-12
JP5567756B2 (ja) 2014-08-06
US8637051B2 (en) 2014-01-28
KR20030019389A (ko) 2003-03-06

Similar Documents

Publication Publication Date Title
CN1437480A (zh) 治疗粘膜感染的组合物和方法
CN1444484A (zh) 用益生菌对粘膜表面的细菌或病毒感染进行治疗或免疫治疗及用于此的组合物
JP2014512388A (ja) 免疫反応を増進するための組成物および方法
JP3919812B2 (ja) Ｈ．ピロリ関連胃十二指腸疾患の治療
CN1338940A (zh) 唾液乳杆菌的应用
US9289483B2 (en) Prophylactic tuberculosis vaccine
US7972609B2 (en) Method of treating cancer
WO2003049751A1 (en) The process of manufacturing a pharmaceutical composition useful for management of cancer
CN111936166B (zh) 用于药物递送的免疫调节和免疫刺激多肽
KR20200009156A (ko) 비피막형 헤모필루스 인플루엔자 백신 및 그의 용도
US20080044440A1 (en) Vaccine Formulated For Administration To Mucosa Of The Lungs
AU2001258060B2 (en) Compositions and methods for treatment of mucosal infections
US7803363B2 (en) Attenuated Francisella bacteria
CN101060852A (zh) 口服灭活疫苗及其提供方法
AU2001258060A1 (en) Compositions and methods for treatment of mucosal infections
AU2001265695A1 (en) Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor.
HK1138786B (en) Prophylactic tuberculosis vaccine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication